Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.
Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...
Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...
Highlighted with 90 tables and 69 figures, this 168-page report ?Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic ...
Ex-Intel head says TSMC’s new investment will not resurrect US chip sector Read the Market Summary Here:- Highlighted with 142 tables and 105 figures, this 228-page report ?Global Pharmaceutical ...
MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...
Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as ...
Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...
Zacks Investment Research on MSN6d
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss DrugViking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback